ADMA
ADMA BIOLOGICS, INC.
$8.21
-1.32%
$1.9B
No data for this timeframe.
Vol
Market Cap$1.9B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (80%)
Inst. Holders50 funds
Inst. Value$1.3B
Inst. Activity22 buys / 25 sells
Insider Activity5B / 3S
Insider Net $-$158.1K
Reddit Sentiment40° Cool
SEC Reports4
Press Releases1
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001368514·Prev Close $8.32
Recent Activity
Jun 11, 2026
SEC
A mixed institutional cluster in ADMA BIOLOGICS for Q3 2024 shows 21 buyers accumulating $86.6M in net new positions (to
INST-CLUSTER — Impact 5/10
May 27, 2026
Insider
Grossman Jerrold B bought 6,400 shares
Director @ $7.91 ($50.6K)
May 12, 2026
Insider
Grossman Jerrold B bought 12,500 shares
Director @ $8.01 ($100.1K)
May 11, 2026
Insider
Grossman Jerrold B bought 12,500 shares
Director @ $8.01 ($100.1K)
May 6, 2026
earnings_calendar
ADMA Q1 2026 Earnings Scheduled — 2026-05-06
May 4, 2026
SEC
ADMA Biologics received FDA approval for label expansion of ASCENIV to include pediatric immune compromised patients age
8-K — Impact 6/10
Apr 15, 2026
SEC
Analysis based on filing metadata only — document content was unavailable
DEFA14A — Impact 2/10
Inst.
Capital Research Global Investors — ADD
11,191,116 shares ($100.8M)
Price Targets
$17.60
+114.4% upside
Strong Buy
Current $8.21
Low $12.00
Median $18.00
High $21.00
5 analysts
$12.00
$21.00
Analyst Ratings
2Strong Buy
6Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 7, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| May 7, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
| Apr 21, 2026 | Canaccord Genuity | INITIATE | Buy |
| Apr 13, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
| Mar 26, 2026 | Cantor Fitzgerald | DOWNGRADE | Overweight → Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.17 ▼ -3.7% | $0.16 — $0.18 | 20% YoY | 3 |
| Next Q | $0.21 ▼ -1.6% | $0.20 — $0.21 | 30% YoY | 3 |
| Current FY | $0.81 ▼ -3.0% | $0.78 — $0.83 | 23% YoY | 2 |
| Next FY | $1.00 ▼ -5.6% | $0.82 — $1.10 | 24% YoY | 4 |
Latest Reports
MIXED
INST-CLUSTER
5/10
A mixed institutional cluster in ADMA BIOLOGICS for Q3 2024 shows 21 buyers accumulating $86.6M in net new positions (to
Jun 11, 2026
BULLISH
8-K
6/10
ADMA Biologics received FDA approval for label expansion of ASCENIV to include pediatric immune compromised patients age
May 4, 2026
MIXED
Press
6/10
ADMA Biologics issued a press release refuting allegations from a short seller report that accused the company of channe
Mar 27, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| NOMURA ASSET MANAGEMENT CO | — | — |
| BlackRock, Inc. | $331.8M | — |
| STATE STREET CORP | $126.9M | — |
| Capital Research Global Investors | $100.8M | ADD |
| VANGUARD CAPITAL MANAGEMENT LLC | $92.9M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 27, 2026 | Grossman Jerrold | BUY | $50.6K |
| May 12, 2026 | Grossman Jerrold | BUY | $100.1K |
| May 11, 2026 | Grossman Jerrold | BUY | $100.1K |
| Apr 1, 2026 | Kestenberg-Messina Kaitlin | F | $185.5K |
| Mar 17, 2026 | Guiheen Lawrence | G | $0.00 |
Reddit Sentiment
40°▲
Cool
Bearish
Neutral
Bullish
50 institutional holders with $1.3B total value (146,356,853 shares) as of 2026-Q1. Top holders: NOMURA, BlackRock,, STATE. Net selling activity: 25 institutions trimmed/exited vs 22 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | NOMURA ASSET MANAGEMENT CO LTD | — | $0.00 | 0.0% | — |
| 2 | BlackRock, Inc. | 36,830,774 | $331.8M | 25.1% | — |
| 3 | STATE STREET CORP | 14,084,205 | $126.9M | 9.6% | — |
| 4 | Capital Research Global Investors | 11,191,116 | $100.8M | 7.6% | ADD +68.6% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 10,306,871 | $92.9M | 7.0% | — |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 8,868,657 | $79.9M | 6.0% | — |
| 7 | Nuveen, LLC | 6,098,225 | $54.9M | 4.2% | — |
| 8 | CITADEL ADVISORS LLC | 5,810,642 | $52.4M | 4.0% | — |
| 9 | DIMENSIONAL FUND ADVISORS LP | 5,005,481 | $45.1M | 3.4% | — |
| 10 | Invesco Ltd. | 4,119,577 | $37.1M | 2.8% | TRIM -65.0% |
| 11 | BANK OF AMERICA CORP /DE/ | 3,997,675 | $36.0M | 2.7% | DOUBLED +107.5% |
| 12 | Point72 Asset Management, L.P. | 3,288,757 | $29.6M | 2.2% | DOUBLED +735.0% |
| 13 | GOLDMAN SACHS GROUP INC | 2,803,530 | $25.3M | 1.9% | — |
| 14 | MORGAN STANLEY | 2,434,379 | $21.9M | 1.7% | — |
| 15 | FRANKLIN RESOURCES INC | 2,344,899 | $21.1M | 1.6% | — |
| 16 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2,095,772 | $18.9M | 1.4% | — |
| 17 | TWO SIGMA INVESTMENTS, LP | 2,092,133 | $18.9M | 1.4% | — |
| 18 | Rubric Capital Management LP | 1,809,408 | $16.3M | 1.2% | NEW |
| 19 | MetLife Investment Management, LLC | 1,738,062 | $15.7M | 1.2% | ADD +25.8% |
| 20 | FEDERATED HERMES, INC. | 1,701,315 | $15.3M | 1.2% | DOUBLED +797.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Capital Research Global Investors | ADD | 6,637,472 | 11,191,116 | +68.6% | $100.8M | 2026-Q1 |
| Invesco Ltd. | TRIM | 11,785,202 | 4,119,577 | -65.0% | $37.1M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 1,926,337 | 3,997,675 | +107.5% | $36.0M | 2026-Q1 |
| Point72 Asset Management, L.P. | DOUBLED | 393,879 | 3,288,757 | +735.0% | $29.6M | 2026-Q1 |
| Rubric Capital Management LP | NEW | — | 1,809,408 | — | $16.3M | 2026-Q1 |
| MetLife Investment Management, LLC | ADD | 1,381,588 | 1,738,062 | +25.8% | $15.7M | 2026-Q1 |
| FEDERATED HERMES, INC. | DOUBLED | 189,659 | 1,701,315 | +797.0% | $15.3M | 2026-Q1 |
| Trexquant Investment LP | DOUBLED | 370,820 | 1,144,841 | +208.7% | $10.3M | 2026-Q1 |
| DEUTSCHE BANK AG\ | TRIM | 1,822,996 | 930,962 | -48.9% | $8.4M | 2026-Q1 |
| Russell Investments Group, Ltd. | TRIM | 1,056,332 | 711,693 | -32.6% | $6.4M | 2026-Q1 |
| TUDOR INVESTMENT CORP ET AL | DOUBLED | 79,506 | 708,089 | +790.6% | $6.4M | 2026-Q1 |
| FIRST TRUST ADVISORS LP | DOUBLED | 24,653 | 360,217 | +1361.1% | $3.2M | 2026-Q1 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | TRIM | 1,023,250 | 296,463 | -71.0% | $2.7M | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | DOUBLED | 18,309 | 272,776 | +1389.8% | $2.5M | 2026-Q1 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | NEAR_EXIT | 1,550,857 | 198,933 | -87.2% | $1.8M | 2026-Q1 |
| ENVESTNET ASSET MANAGEMENT INC | ADD | 79,179 | 122,790 | +55.1% | $1.1M | 2026-Q1 |
| Vident Advisory, LLC | TRIM | 270,492 | 120,835 | -55.3% | $1.1M | 2026-Q1 |
| JANUS HENDERSON GROUP PLC | NEAR_EXIT | 3,936,419 | 98,261 | -97.5% | $883.9K | 2026-Q1 |
| VOYA INVESTMENT MANAGEMENT LLC | NEAR_EXIT | 2,012,096 | 89,795 | -95.5% | $809.1K | 2026-Q1 |
| CAPTRUST FINANCIAL ADVISORS | ADD | 63,577 | 88,032 | +38.5% | $793.2K | 2026-Q1 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | ADD | 51,271 | 83,356 | +62.6% | $751.0K | 2026-Q1 |
| Merit Financial Group, LLC | DOUBLED | 10,594 | 74,444 | +602.7% | $670.7K | 2026-Q1 |
| GROUP ONE TRADING LLC | TRIM | 191,264 | 70,183 | -63.3% | $632.3K | 2026-Q1 |
| FIFTH THIRD BANCORP | DOUBLED | 705 | 55,508 | +7773.5% | $500.1K | 2026-Q1 |
| Amundi | ADD | 31,776 | 51,761 | +62.9% | $466.4K | 2026-Q1 |
9 unique insiders with 39 transactions. Net insider value: -$158.1K ($468.3K bought, $626.4K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 27, 2026 | Grossman Jerrold B | Director | BUY | 6,400 | $7.91 | $50.6K |
| May 12, 2026 | Grossman Jerrold B | Director | BUY | 12,500 | $8.01 | $100.1K |
| May 11, 2026 | Grossman Jerrold B | Director | BUY | 12,500 | $8.01 | $100.1K |
| Apr 1, 2026 | Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | TAX W/H | 20,362 | $9.11 | $185.5K |
| Mar 17, 2026 | Guiheen Lawrence P. | Director | GIFT | 30,000 | — | — |
| Mar 16, 2026 | Grossman Adam S | President and CEO | SELL | 15,000 | $15.16 | $227.4K |
| Mar 16, 2026 | Grossman Adam S | President and CEO | EXERCISE | 15,000 | $5.40 | $81.0K |
| Mar 13, 2026 | Guiheen Lawrence P. | Director | EXERCISE | 30,000 | $3.66 | $109.8K |
| Mar 9, 2026 | Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | SELL | 10,096 | $15.63 | $157.8K |
| Mar 9, 2026 | Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | EXERCISE | 2,500 | $5.00 | $12.5K |
| Mar 9, 2026 | Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | J | 91,266 | — | — |
| Mar 7, 2026 | Grossman Adam S | President and CEO | TAX W/H | 29,513 | $15.39 | $454.2K |
| Mar 7, 2026 | Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | TAX W/H | 4,235 | $15.39 | $65.2K |
| Mar 6, 2026 | ELMS STEVE | Director | BUY | 7,000 | $15.39 | $107.7K |
| Mar 6, 2026 | Grossman Adam S | President and CEO | TAX W/H | 56,438 | $15.39 | $868.6K |
| Mar 6, 2026 | Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | TAX W/H | 10,059 | $15.39 | $154.8K |
| Mar 5, 2026 | ELMS STEVE | Director | BUY | 7,000 | $15.67 | $109.7K |
| Feb 26, 2026 | Grossman Adam S | President and CEO | TAX W/H | 54,858 | $15.18 | $832.7K |
| Feb 19, 2026 | Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | TAX W/H | 8,161 | $16.32 | $133.2K |
| Feb 19, 2026 | Grossman Adam S | President and CEO | TAX W/H | 24,793 | $16.32 | $404.6K |
| Feb 19, 2026 | Tade Brad L. | CFO and Treasurer | TAX W/H | 6,479 | $16.32 | $105.7K |
| Feb 17, 2026 | Grossman Adam S | President and CEO | EXERCISE | 15,000 | $5.40 | $81.0K |
| Feb 17, 2026 | Grossman Adam S | President and CEO | SELL | 15,000 | $16.08 | $241.2K |
| Feb 9, 2026 | Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | AWARD | 144,230 | — | — |
| Feb 9, 2026 | Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance | AWARD | 91,631 | — | — |
| Feb 9, 2026 | Grossman Adam S | President and CEO | AWARD | 444,711 | — | — |
| Feb 9, 2026 | Grossman Adam S | President and CEO | AWARD | 282,529 | — | — |
| Feb 9, 2026 | KWON YOUNG | Director | AWARD | 17,730 | — | — |
| Feb 9, 2026 | KWON YOUNG | Director | AWARD | 10,690 | — | — |
| Feb 9, 2026 | FINGER ALISON CECILY | Director | AWARD | 17,730 | — | — |
| Feb 9, 2026 | FINGER ALISON CECILY | Director | AWARD | 10,690 | — | — |
| Feb 9, 2026 | Salas Eduardo Rene | Director | AWARD | 17,730 | — | — |
| Feb 9, 2026 | Salas Eduardo Rene | Director | AWARD | 10,690 | — | — |
| Feb 9, 2026 | Guiheen Lawrence P. | Director | AWARD | 17,730 | — | — |
| Feb 9, 2026 | Guiheen Lawrence P. | Director | AWARD | 10,690 | — | — |
| Feb 9, 2026 | ELMS STEVE | Director | AWARD | 17,730 | — | — |
| Feb 9, 2026 | ELMS STEVE | Director | AWARD | 10,690 | — | — |
| Feb 9, 2026 | Grossman Jerrold B | Director | AWARD | 17,730 | — | — |
| Feb 9, 2026 | Grossman Jerrold B | Director | AWARD | 10,690 | — | — |
4 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 1 mixed, 1 neutral. Avg impact: 5.3/10.
MIXED
INST-CLUSTER
5/10
A mixed institutional cluster in ADMA BIOLOGICS for Q3 2024 shows 21 buyers accumulating $86.6M in n
Jun 11, 2026
BULLISH
8-K
6/10
ADMA Biologics received FDA approval for label expansion of ASCENIV to include pediatric immune comp
May 4, 2026
NEUTRAL
DEFA14A
2/10
Analysis based on filing metadata only — document content was unavailable
Apr 15, 2026
BULLISH
8-K
8/10
ADMA Biologics reported record financial results for 2025 with 20% YoY revenue growth to $510 millio
Feb 25, 2026
Current analyst consensus: Strong Buy (80% buy). Based on 10 analysts: 2 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$17.60 mean target
+114.4% upside
Strong Buy (1.60)
$12.00 Low
$21.00 High
| Metric | Value |
|---|---|
| Current Price | $8.21 |
| Target Low | $12.00 |
| Target Mean | $17.60 |
| Target Median | $18.00 |
| Target High | $21.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (1.60) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.17 | $0.16 | $0.18 | 19.5% | -3.7% | 0↑ 1↓ | $0.1B | 3.4% | 3 |
| Next Q 2026-09-30 |
$0.21 | $0.20 | $0.21 | 30.0% | -1.6% | 0↑ 1↓ | $0.1B | 3.5% | 3 |
| Current FY 2026-12-31 |
$0.81 | $0.78 | $0.83 | 22.6% | -3.0% | 0↑ 1↓ | $0.5B | 4.8% | 2 |
| Next FY 2027-12-31 |
$1.00 | $0.82 | $1.10 | 23.9% | -5.6% | 0↑ 1↓ | $0.7B | 31.1% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.173 | |
| 7d ago | $0.180 | -0.007 |
| 30d ago | $0.180 | -0.007 |
| 60d ago | $0.250 | -0.077 |
| 90d ago | $0.250 | -0.077 |
3 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 7, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| May 7, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Apr 21, 2026 | Canaccord Genuity | INITIATE | — | Buy |
| Apr 13, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Mar 26, 2026 | Cantor Fitzgerald | DOWNGRADE | Overweight | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 6 | 2 | 0 | 0 | 80% | |
| May 1, 2026 | 2 | 6 | 2 | 0 | 0 | 80% | |
| Apr 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Mar 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Jan 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
40°
Cool
Bearish
Neutral
Bullish
6 mentions
0 bullish
2 bearish
6 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 31, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| May 31, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Mar 27, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 27, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 26, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 26, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
May 6, 2026
earnings_calendar
ADMA Q1 2026 Earnings Scheduled — 2026-05-06
May 5, 2026
earnings_calendar
ADMA Q1 2026 Earnings Scheduled — 2026-05-05
Apr 29, 2026
earnings
ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026
Conference Call Scheduled for May 6, 2026, at 4:30 p.m. ET <pre>Conference Call Scheduled for May 6, 2026, at 4:30 p.m. ET</pre>
Apr 21, 2026
short_volume
Short Volume: ADMA — 56.3% short (1.2M / 2.2M)
Short: 1,230,191 | Exempt: 15,875 | TRF Vol: 2,183,762 | Short Ratio: 56.3% | Off-exchange volume (dark pool + OTC)
Mar 27, 2026
activist
ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research
<p align="center"><em>Short seller’s Characterization of ASCENIV’s Competitive Position Reflects Blatant Misunderstanding of ADMA’s Business and Its R
Mar 25, 2026
other
ADMA Biologics Addresses Misleading Short-Seller Report
<p align="justify">RAMSEY, N.J. and BOCA RATON, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company
Mar 16, 2026
short_interest
FTD: ADMA — 36,705 shares ($0.6M) failed to deliver
Settlement: 20260316, Price: $15.15, FTD Value: $556,080.75, ADMA BIOLOGICS INC COM
Feb 25, 2026
earnings_calendar
ADMA Q4 2025 Earnings After Market Close — 2026-02-25